search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Tracleer in Behçet's disease


- candidate number3566
- NTR NumberNTR1372
- ISRCTNISRCTN wordt niet meer aangevraagd
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR8-jul-2008
- Secondary IDs2008-042 METC Erasmus MC Rotterdam
- Public TitleTracleer in Behçet's disease
- Scientific TitleBosentan (Tracleer) in patients with Behçet's disease: a Pilot Study.
- ACRONYMN/A
- hypothesisTherapeutic effect of bosentan in patients with Behçet's disease due to antiinflammatory effects on the vascular wall.
- Healt Condition(s) or Problem(s) studiedVasculitis, BehÁet's disease, Bosentan, Endothelin-1 (ET-1)
- Inclusion criteria1. BD patients classified according to the criteria according to the International study group for BD
2. BD patients not responding to their usual therapy (BDCAF > 20)
3. Non life-or sight threatening active disease.
4. Adequate birth control measures in women of childbearing age during and for 6 weeks after receiving the last administration.
5. The screening laboratory test results must meet the following criteria:
- Hemoglobin °› 6.5 mmol/L.
- WBC °› 3.0 x 109/L.
- Neutrophils °› 1.5 x 109/L.
- Platelets °› 100 x 109/L.
- SGOT (AST), SGPT (ALT) and alkaline phosphatase levels must be within 3 times the upper limit of normal (ULN) range for the laboratory conducting the test.
- Creatinine clearance > 20 ml/min.
6. Patient must be able to adhere to the study visit schedule and other protocol requirements.
7. The patient must be capable of giving informed consent and the consent must be obtained prior to any screening procedures.
- Exclusion criteria1. Age < 18 years.
2. Women who are pregnant, nursing, or planning pregnancy within 38 weeks after enrollment.
3. Hypotension, defined as systolic blood pressure less than 85 mm Hg
4. Use of any of the following drugs: glybenclamide, calcineurin inhibitors (eg, cyclosporine A, tacrolimus) or fluconazole. Attention must be focused on liverenzymes and adverse effects if the patient uses other drugs that interfere with CYP-450 isoenzymes such as listed in paragraph 11.
5. Use of any investigational drug within 1 month prior to screening or within 5 half-lives of the investigational agent, whichever is longer.
6. Liver enzymes > 3 times the ULN, Creatinine clearance of < 20ml/min.
7. Patients with known hypersensitivity to Bosentan or to drugs with similar chemical structures.
8. Current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, infectious or cerebral disease.
9. Malignancy within the past 5 years (except for treated squamous or basal cell carcinoma of the skin without evidence of recurrence).
10. Known recent substance abuse (drugs or alcohol).
11. Poor tolerability of venipuncture or lack of adequate venous access for required blood sampling during the study period.
- mec approval receivedyes
- multicenter trialno
- randomisedyes
- masking/blindingDouble
- controlPlacebo
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-sep-2008
- planned closingdate1-okt-2010
- Target number of participants20
- InterventionsDouble-blind, randomized.
Bosentan 2 x 125 vs placebo 6 months, follow up 2 more months
- Primary outcome- A decrease in the score in the BDCAF of > 10 in patients with BD with a BDCAF score of > 20
- Secondary outcome- ET-1 levels in relation with BDCAF.
- Study of cytokine patterns in relation with therapy and BDCAF.
- T cell patterns in relation with therapy and BDCAF.
- TimepointsWeek 0, 4, 8, 12, 16, 20, 24, 28, 32
- Trial web siteN/A
- statusplanned
- CONTACT FOR PUBLIC QUERIES J.A.M. Laar van
- CONTACT for SCIENTIFIC QUERIES J.A.M. Laar van
- Sponsor/Initiator Erasmus Medical Center
- Funding
(Source(s) of Monetary or Material Support)
Actelion Pharmaceuticals
- PublicationsN/A
- Brief summaryPatients with Behcet's disease refractory for immunosuppressive therapy (BDCAF >20) are randomized for add on treatment with bosentan for 6 months. Therapeutic efficacy will be measured with a standarized activity scoring system (BDCAF), and analyzed with secundary parameters such as ET-1 levels, cytokines and Tcell functionality.
- Main changes (audit trail)
- RECORD8-jul-2008 - 25-jul-2008


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl